15
Participants
Start Date
October 9, 2020
Primary Completion Date
November 9, 2020
Study Completion Date
November 9, 2020
Ralinepag
"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
Peking University Third Hospital, Beijing
Everstar Medicines (Shanghai) Limited
INDUSTRY